Abstract
MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Current Molecular Medicine
Title:Role of MicroRNAs in B Cell Leukemias and Lymphomas
Volume: 14 Issue: 5
Author(s): A. Schmidt and R. Kuppers
Affiliation:
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Abstract: MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Export Options
About this article
Cite this article as:
Schmidt A. and Kuppers R., Role of MicroRNAs in B Cell Leukemias and Lymphomas, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603095414
DOI https://dx.doi.org/10.2174/1566524014666140603095414 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer
Current Cancer Therapy Reviews Application of Chemistry-Based Functional Proteomics to Screening for Novel Drug Targets
Combinatorial Chemistry & High Throughput Screening Bone Marrow Reconstitution as a Relevant Model of Genetically Programmed Leukemia
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Frontier Lipid-Based Carrier Systems for Drug Targeting: A Laconic Review on Niosomes
Pharmaceutical Nanotechnology Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Current Drug Targets BAFFling Autoimmune Disorders and Helicobacter pylori Disease: The Interplay between BAFF and the Th17 Response
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets Double-Strand Breaks Repair by Non-Homologous DNA End Joining in Mammalian Cells
Current Genomics Small Molecule Inhibitors of Protein Kinases in Cancer- How to Overcome Resistance
Mini-Reviews in Medicinal Chemistry Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry New Insights on the Antitumoral Properties of Prodiginines
Current Medicinal Chemistry Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Molecular Recognition Mechanisms for Detecting Cell Death In Vivo
Current Pharmaceutical Biotechnology